Abstract
Background: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, with an incidence of 3.19 cases per 100,000 person years and remarkably poor prognosis showing a 5-year survival rate of 4-5%, and only a 26-33% survival rate at 2 years in clinical trials.
Objective: In this paper, we review the different types of treatment modalities based on the relevant databases. Methods of diagnosis will be described briefly.
Method: Systemic compilation of the relevant literature.
Results & Conclusion: Today's treatments cannot cure GBM patients but only extend their overall survival. The use of chemoradiation, immunotherapy, and radio sensitizers as an adjuvant therapy cannot reduce the high rates of recurrence within a few months after treatment. Radiotherapy will remain the backbone of the treatment but new treatment modalities must be developed.
Keywords: Biologic agent, chemotherapy, glioblastoma multiforme, immunotherapy, radiation therapy, vaccination.
Current Medicinal Chemistry
Title:Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review
Volume: 24 Issue: 27
Author(s): Ron Batash , Noam Asna *, Pamela Schaffer, Nicole Francis and Moshe Schaffer
Affiliation:
- Barzilai Medical Center, Department of Oncology, Ashkelon,Israel
Keywords: Biologic agent, chemotherapy, glioblastoma multiforme, immunotherapy, radiation therapy, vaccination.
Abstract: Background: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, with an incidence of 3.19 cases per 100,000 person years and remarkably poor prognosis showing a 5-year survival rate of 4-5%, and only a 26-33% survival rate at 2 years in clinical trials.
Objective: In this paper, we review the different types of treatment modalities based on the relevant databases. Methods of diagnosis will be described briefly.
Method: Systemic compilation of the relevant literature.
Results & Conclusion: Today's treatments cannot cure GBM patients but only extend their overall survival. The use of chemoradiation, immunotherapy, and radio sensitizers as an adjuvant therapy cannot reduce the high rates of recurrence within a few months after treatment. Radiotherapy will remain the backbone of the treatment but new treatment modalities must be developed.
Export Options
About this article
Cite this article as:
Batash Ron , Asna Noam*, Schaffer Pamela, Francis Nicole and Schaffer Moshe , Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review, Current Medicinal Chemistry 2017; 24 (27) . https://dx.doi.org/10.2174/0929867324666170516123206
DOI https://dx.doi.org/10.2174/0929867324666170516123206 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry Coagulation and Cancer Therapy: The Potential of Natural Compounds
Current Genomics Identification of Tumor Targeting Agents by Phage Display
Medicinal Chemistry Reviews - Online (Discontinued) Selectively Replicating Adenoviruses for Oncolytic Therapy
Current Cancer Drug Targets The Functional Role of Oncogenic LncRNA BCAR4 for Cancer Outcome
Current Pharmaceutical Design Editorial [Hot Topic:Angiogenesis Agents(Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design Magnetic Resonance Diffusion Tensor Imaging and Diffusion Tensor Tractography in the Evaluation of Congenital and Acquired Diseases of the Pediatric Visual System
Current Pediatric Reviews Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design Transporter-Based Delivery of Anticancer Drugs to the Brain: Improving Brain Penetration by Minimizing Drug Efflux at the Blood-Brain Barrier
Current Pharmaceutical Design Cancer Gene Therapy Utilizing Interleukin-13 Receptor α2 Chain
Current Gene Therapy Summary of Information on the Effects of Ionizing and Non-ionizing Radiation on Cytochrome P450 and Other Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism Ribozymes in the Age of Molecular Therapeutics
Current Molecular Medicine Role of Protein Tyrosine Phosphatase in Regulation of Cell Signaling Cascades Affecting Tumor Cell Growth: A Future Perspective as Anti-Cancer Drug Target
Current Pharmaceutical Biotechnology Relationship with Programmed Cell Death Ligand 1 (PD-L1) and DTI Features in Brain Metastases of Non-small Cell Lung Cancer: A Preliminary Study
Current Medical Imaging Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology The Interaction Between FAK, MYCN, p53 and Mdm2 in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Clonetics
Current Drug Metabolism Recent Development in Fluorescent Probes for Copper Ion Detection
Current Topics in Medicinal Chemistry